ATE213627T1 - Orale zeitversetzt schnell freisetzende formulierung sowie verfahren zu deren herstellung - Google Patents

Orale zeitversetzt schnell freisetzende formulierung sowie verfahren zu deren herstellung

Info

Publication number: ATE213627T1
Authority: AT; Austria
Prior art keywords: immediate release; compounds; release formulation; oral delayed; oral
Prior art date: 1996-09-23

Application number

AT97943895T

Other languages

English (en)

Inventor

Balken Paulus Maria Van

Jules Alex Cornelis Elbers

Henderik Willem Frijlink

Wienman Emerald Philips

Original Assignee

Duphar Int Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-23

Filing date

1997-09-18

Publication date

2002-03-15

1997-09-18 Application filed by Duphar Int Res filed Critical Duphar Int Res

2002-03-15 Application granted granted Critical

2002-03-15 Publication of ATE213627T1 publication Critical patent/ATE213627T1/de

Links

238000009472 formulation Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 7
239000012729 immediate-release (IR) formulation Substances 0.000 abstract 7
230000003111 delayed effect Effects 0.000 abstract 5
239000013543 active substance Substances 0.000 abstract 3
230000003110 anti-inflammatory effect Effects 0.000 abstract 2
239000011248 coating agent Substances 0.000 abstract 2
238000000576 coating method Methods 0.000 abstract 2
230000002496 gastric effect Effects 0.000 abstract 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
229940123907 Disease modifying antirheumatic drug Drugs 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000000049 anti-anxiety effect Effects 0.000 abstract 1
230000002456 anti-arthritic effect Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000003474 anti-emetic effect Effects 0.000 abstract 1
230000003276 anti-hypertensive effect Effects 0.000 abstract 1
230000003356 anti-rheumatic effect Effects 0.000 abstract 1
230000000767 anti-ulcer Effects 0.000 abstract 1
230000001362 anti-vertigo Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
239000000935 antidepressant agent Chemical class 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
239000002111 antiemetic agent Substances 0.000 abstract 1
229940125683 antiemetic agent Drugs 0.000 abstract 1
239000002220 antihypertensive agent Chemical class 0.000 abstract 1
229940030600 antihypertensive agent Drugs 0.000 abstract 1
239000003435 antirheumatic agent Substances 0.000 abstract 1
239000002249 anxiolytic agent Chemical class 0.000 abstract 1
239000000496 cardiotonic agent Substances 0.000 abstract 1
230000003177 cardiotonic effect Effects 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
239000003246 corticosteroid Substances 0.000 abstract 1
229960001334 corticosteroids Drugs 0.000 abstract 1
239000012530 fluid Substances 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
239000000932 sedative agent Chemical class 0.000 abstract 1
229940125723 sedative agent Drugs 0.000 abstract 1
230000002522 swelling effect Effects 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1
229940124549 vasodilator Drugs 0.000 abstract 1
239000003071 vasodilator agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Virology (AREA)
Pulmonology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Cosmetics (AREA)

AT97943895T 1996-09-23 1997-09-18 Orale zeitversetzt schnell freisetzende formulierung sowie verfahren zu deren herstellung ATE213627T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP96202651		1996-09-23
PCT/EP1997/005234 WO1998013029A1 (en)	1996-09-23	1997-09-18	Oral delayed immediate release formulation and method of preparation therefor

Publications (1)

Publication Number	Publication Date
ATE213627T1 true ATE213627T1 (de)	2002-03-15

Family

ID=8224414

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97943895T ATE213627T1 (de)	1996-09-23	1997-09-18	Orale zeitversetzt schnell freisetzende formulierung sowie verfahren zu deren herstellung

Country Status (29)

Country	Link
US (1)	US6183780B1 (de)
EP (1)	EP0939623B1 (de)
JP (1)	JP4947824B2 (de)
KR (1)	KR100501966B1 (de)
CN (1)	CN1161110C (de)
AT (1)	ATE213627T1 (de)
AU (1)	AU717711B2 (de)
BR (1)	BR9711303A (de)
CA (1)	CA2263921C (de)
CZ (1)	CZ294641B6 (de)
DE (1)	DE69710756T2 (de)
DK (1)	DK0939623T3 (de)
DZ (1)	DZ2314A1 (de)
ES (1)	ES2172003T3 (de)
HR (1)	HRP970493A2 (de)
HU (1)	HU226693B1 (de)
ID (1)	ID22039A (de)
IL (1)	IL128565A (de)
JO (1)	JO2066B1 (de)
NO (1)	NO325763B1 (de)
NZ (1)	NZ334463A (de)
PL (1)	PL189016B1 (de)
PT (1)	PT939623E (de)
RU (1)	RU2193395C2 (de)
SK (1)	SK284263B6 (de)
TR (1)	TR199900641T2 (de)
UA (1)	UA72182C2 (de)
WO (1)	WO1998013029A1 (de)
ZA (1)	ZA978431B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030109503A1 (en) *	1995-06-06	2003-06-12	Smithkline Beecham P.L.C.	Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
TR200003435T2 (tr) *	1998-05-20	2001-03-21	The Liposome Company,Inc.	Yeni parçacıklı formülasyonlar
SE9802973D0 (sv)	1998-09-03	1998-09-03	Astra Ab	Immediate release tablet
US20010055613A1 (en) *	1998-10-21	2001-12-27	Beth A. Burnside	Oral pulsed dose drug delivery system
NZ511442A (en) *	1998-11-02	2003-02-28	Elan Corp Plc	Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US7250176B1 (en) *	1999-04-13	2007-07-31	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection
US6878386B1 (en)	1999-04-13	2005-04-12	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en)	1999-04-13	2001-09-25	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising administering amoxycillin
IE990406A1 (en) *	1999-05-20	2000-12-27	Elan Corp Plc	Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP1064937A1 (de) *	1999-06-28	2001-01-03	Sanofi-Synthelabo	Pharmazeutische Zusammensetzungen mit kontrollierten Freigabe enthaltend ein Hypnotikum mit kurzer Wirkung oder deren Salze
EP1074249A1 (de) *	1999-07-27	2001-02-07	Jagotec Ag	Pharmazeutisches Tablettensystem zur Freisetzung zumindest eines Wirkstoffs während einer sich an einen Nicht-Freisetzungszeitabschitt anschliessende Freisetzungszeit
IL148247A0 (en)	1999-08-24	2002-09-12	Teva Pharma	A vaccine composition and method of using the same
US6592869B2 (en)	1999-08-24	2003-07-15	Teva Pharmaceutical Industries, Ltd.	Vaccine composition and method of using the same
US6485746B1 (en)	2000-08-25	2002-11-26	Neurocrine Biosciences, Inc.	Controlled-release sedative-hypnotic compositions and methods related thereto
AU7335500A (en) *	1999-08-26	2001-03-19	Neurocrine Biosciences, Inc.	Controlled-release sedative-hypnotic compositions and methods related thereto
DE10012555A1 (de) *	2000-03-15	2001-09-20	Merck Patent Gmbh	Glucocorticoide in einer Modified Release-Formulierung
US6720005B1 (en) *	2000-07-07	2004-04-13	The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Coated, platform-generating tablet
EP1330236A2 (de)	2000-10-12	2003-07-30	Beecham Pharmaceuticals (Pte) Limited	Amoxicillinhaltige arzneizusammensetzungen
US6756057B2 (en)	2000-10-12	2004-06-29	Beecham Pharmaceuticals (Pte) Limited	Amoxicillin and potassium clavulanate dosage form
US6913768B2 (en) *	2002-09-24	2005-07-05	Shire Laboratories, Inc.	Sustained release delivery of amphetamine salts
US20080220074A1 (en) *	2002-10-04	2008-09-11	Elan Corporation Plc	Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US20070148229A1 (en) *	2003-04-24	2007-06-28	Jagotec Ag	Tablet with coloured core
CA2523158C (en)	2003-04-24	2010-11-16	Jagotec Ag	Delayed release tablet with defined core geometry
PT1575565E (pt) *	2003-08-08	2010-03-03	Biovail Lab Int Srl	Comprimido de libertação modificada de cloridrato de bupropiona
EP1682537B1 (de)	2003-11-05	2012-03-28	SARcode Bioscience Inc.	Modulatoren der zellulären adhäsion
EP1750862B1 (de) *	2004-06-04	2011-01-05	Teva Pharmaceutical Industries Ltd.	Irbesartan enthaltende pharmazeutische zusammensetzung
DE102004043863A1 (de)	2004-09-10	2006-03-16	Nitec Pharma Ag	Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
GB0423964D0 (en) *	2004-10-28	2004-12-01	Jagotec Ag	Dosage form
US20060121112A1 (en) *	2004-12-08	2006-06-08	Elan Corporation, Plc	Topiramate pharmaceutical composition
CA2602268A1 (en) *	2005-04-12	2006-10-19	Elan Pharma International Limited	Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
DK1881823T3 (en)	2005-05-17	2015-03-02	Sarcode Bioscience Inc	COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
US20100136106A1 (en) *	2005-06-08	2010-06-03	Gary Liversidge	Modified Release Famciclovir Compositions
CA2617051C (en)	2005-07-29	2013-12-17	Stichting Groningen Centre For Drug Research	Ph-controlled pulsatile delivery system, methods for preparation and use thereof
US20070036859A1 (en) *	2005-08-11	2007-02-15	Perry Ronald L	Sustained release antihistamine and decongestant composition
TWI274889B (en) *	2005-10-06	2007-03-01	Elan Microelectronics Corp	Resistive touch screen measurement system
WO2007072495A2 (en) *	2005-11-03	2007-06-28	Sun Pharmaceutical Industries Limited	Coated tablets having prolonged gastric retention
RU2308941C1 (ru) *	2006-05-10	2007-10-27	Открытое акционерное общество "Московское производственное химико-фармацевтическое объединение им. Н.А. Семашко"	Твердая лекарственная форма, обладающая гистаминоподобным действием, и способ ее получения
SG174026A1 (en) *	2006-08-03	2011-09-29	Nitec Pharma Ag	Delayed-release glucocorticoid treatment of rheumatoid disease
US20080081067A1 (en) *	2006-10-03	2008-04-03	Gupta Manishkumar	Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
RU2356539C2 (ru) *	2006-12-28	2009-05-27	Закрытое Акционерное Общество "Канонфарма Продакшн"	Твердая лекарственная форма бетагистина дигидрохлорида и способ ее получения
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en)	2007-06-04	2013-11-28	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en)	2008-06-04	2010-05-13	Synergy Pharmaceuticals, Inc.	Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
WO2009021127A2 (en) *	2007-08-07	2009-02-12	Neurogen Corporation	Controlled released compositions
AU2008317473B2 (en)	2007-10-19	2014-07-17	Bausch + Lomb Ireland Limited	Compositions and methods for treatment of diabetic retinopathy
WO2009139817A2 (en)	2008-04-15	2009-11-19	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
EP2391369A1 (de) *	2009-01-26	2011-12-07	Nitec Pharma AG	Glukokortikoid-behandlung von asthma mit verzögerter freisetzung
NZ582836A (en) *	2009-01-30	2011-06-30	Nitec Pharma Ag	Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2011050175A1 (en)	2009-10-21	2011-04-28	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
EP2314296A1 (de) *	2009-10-22	2011-04-27	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Im Mund zerfallende Betahistin Tabletten
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012071220A1 (en) *	2010-11-23	2012-05-31	Transcept Pharmaceuticals, Inc.	Compositions and methods for once-daily administration of a trilayer osmotic tablet
RU2453308C1 (ru) *	2010-12-20	2012-06-20	Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ"	Драже с оксиметилурацилом и мебеверина гидрохлоридом для лечения функциональных заболеваний желудочно-кишечного тракта
KR102258769B1 (ko) *	2011-10-14	2021-06-01	지엘팜텍주식회사	장용소화효소제 및 그 제조방법
DE102012105528A1 (de)	2012-06-25	2014-01-02	Hennig Arzneimittel Gmbh & Co. Kg	Arzneiform zur Freisetzung von Wirkstoffen
WO2014018748A1 (en)	2012-07-25	2014-01-30	Sarcode Bioscience Inc.	Lfa-1 inhibitor and polymorph thereof
US9545446B2 (en)	2013-02-25	2017-01-17	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
HK1220611A1 (zh)	2013-03-15	2017-05-12	Bausch Health Ireland Limited	用於治疗胃肠道病症的组成物
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
EP3054969B1 (de)	2013-10-10	2021-03-10	Bausch Health Ireland Limited	Gunaylatcyclase-cyclase-agonisten zur behandlung von opioidinduzierten störungen
US10294228B2 (en) *	2015-06-30	2019-05-21	Neurad Ltd.	Breathing control modulating compounds, and methods of making and using same
CA3009814A1 (en)	2016-01-11	2017-07-20	Synergy Pharmaceuticals, Inc.	Formulations and methods for treating ulcerative colitis
CN108836948B (zh) *	2018-06-11	2024-04-12	宁波西敦医药包衣科技有限公司	一种利用包衣技术实现营养素可控制释放的产品
RU2695135C1 (ru) *	2018-07-11	2019-07-22	Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства	Двухуровневая микрогранулированная форма терапевтического пептида для перорального применения и способ ее получения
CN110403912A (zh) *	2019-09-04	2019-11-05	西安科力康医药科技有限公司	缓控释包衣粉

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH666405A5 (de) *	1985-06-24	1988-07-29	Ciba Geigy Ag	Feste, haltbare darreichungsformen mit elastischem filmueberzug.
GB8524001D0 (en) *	1985-09-30	1985-11-06	Glaxo Group Ltd	Pharmaceutical composition
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5122384A (en) *	1989-05-05	1992-06-16	Kv Pharmaceutical Company	Oral once-per-day organic nitrate formulation which does not induce tolerance
US5032405A (en) *	1989-09-27	1991-07-16	Warner-Lambert Company	Oral pharmaceutical composition for acid sensitive proteinaceous agents
FR2655266B1 (fr) *	1989-12-05	1992-04-03	Smith Kline French Lab	Compositions pharmaceutiques a base de cimetidine.
US5229131A (en) *	1990-02-05	1993-07-20	University Of Michigan	Pulsatile drug delivery system
US5158777A (en) *	1990-02-16	1992-10-27	E. R. Squibb & Sons, Inc.	Captopril formulation providing increased duration of activity
GB9104854D0 (en) *	1991-03-07	1991-04-17	Reckitt & Colmann Prod Ltd	Sustained release compositions
US5286497A (en)	1991-05-20	1994-02-15	Carderm Capital L.P.	Diltiazem formulation
RU2120798C1 (ru) *	1991-11-22	1998-10-27	Проктер энд Гэмбл Фармасьютикалз, Инк.	Твердая фармацевтическая композиция для перорального введения
WO1993019741A1 (en) *	1992-03-31	1993-10-14	Benzon Pharma A/S	A pharmaceutical formulation
US5500227A (en) *	1993-11-23	1996-03-19	Euro-Celtique, S.A.	Immediate release tablet cores of insoluble drugs having sustained-release coating
JP2977907B2 (ja) *	1994-05-06	1999-11-15	ファイザー・インコーポレーテッド	アジスロマイシンの放出調節された剤形

1997
- 1997-09-16 HR HR96202651,4A patent/HRP970493A2/hr not_active Application Discontinuation
- 1997-09-18 ID IDW990114A patent/ID22039A/id unknown
- 1997-09-18 NZ NZ334463A patent/NZ334463A/xx not_active IP Right Cessation
- 1997-09-18 WO PCT/EP1997/005234 patent/WO1998013029A1/en not_active Ceased
- 1997-09-18 HU HU9904121A patent/HU226693B1/hu not_active IP Right Cessation
- 1997-09-18 IL IL12856597A patent/IL128565A/xx not_active IP Right Cessation
- 1997-09-18 CA CA002263921A patent/CA2263921C/en not_active Expired - Fee Related
- 1997-09-18 PL PL97332245A patent/PL189016B1/pl not_active IP Right Cessation
- 1997-09-18 DK DK97943895T patent/DK0939623T3/da active
- 1997-09-18 AU AU45570/97A patent/AU717711B2/en not_active Ceased
- 1997-09-18 EP EP97943895A patent/EP0939623B1/de not_active Expired - Lifetime
- 1997-09-18 TR TR1999/00641T patent/TR199900641T2/xx unknown
- 1997-09-18 UA UA99042314A patent/UA72182C2/uk unknown
- 1997-09-18 ES ES97943895T patent/ES2172003T3/es not_active Expired - Lifetime
- 1997-09-18 BR BR9711303A patent/BR9711303A/pt not_active Application Discontinuation
- 1997-09-18 JP JP51526398A patent/JP4947824B2/ja not_active Expired - Fee Related
- 1997-09-18 AT AT97943895T patent/ATE213627T1/de active
- 1997-09-18 SK SK376-99A patent/SK284263B6/sk not_active IP Right Cessation
- 1997-09-18 CN CNB971981671A patent/CN1161110C/zh not_active Expired - Fee Related
- 1997-09-18 CZ CZ1999995A patent/CZ294641B6/cs not_active IP Right Cessation
- 1997-09-18 PT PT97943895T patent/PT939623E/pt unknown
- 1997-09-18 RU RU99108461/14A patent/RU2193395C2/ru not_active IP Right Cessation
- 1997-09-18 DE DE69710756T patent/DE69710756T2/de not_active Expired - Lifetime
- 1997-09-18 ZA ZA9708431A patent/ZA978431B/xx unknown
- 1997-09-18 KR KR10-1999-7002380A patent/KR100501966B1/ko not_active Expired - Fee Related
- 1997-09-19 US US08/934,196 patent/US6183780B1/en not_active Expired - Lifetime
- 1997-09-21 JO JO19972066A patent/JO2066B1/en active
- 1997-09-22 DZ DZ970164A patent/DZ2314A1/xx active
1999
- 1999-03-22 NO NO19991385A patent/NO325763B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
PL189016B1 (pl)	2005-06-30
EP0939623B1 (de)	2002-02-27
DE69710756T2 (de)	2002-10-24
DE69710756D1 (de)	2002-04-04
KR100501966B1 (ko)	2005-07-20
SK37699A3 (en)	1999-08-06
NZ334463A (en)	2000-12-22
TR199900641T2 (xx)	1999-07-21
US6183780B1 (en)	2001-02-06
CA2263921A1 (en)	1998-04-02
NO991385L (no)	1999-05-25
KR20010029536A (ko)	2001-04-06
HRP970493A2 (en)	1998-08-31
JO2066B1 (en)	2000-05-21
HUP9904121A2 (hu)	2000-04-28
EP0939623A1 (de)	1999-09-08
CN1161110C (zh)	2004-08-11
CN1231601A (zh)	1999-10-13
HK1019852A1 (en)	2000-03-03
PT939623E (pt)	2002-08-30
ID22039A (id)	1999-08-26
ES2172003T3 (es)	2002-09-16
UA72182C2 (en)	2005-02-15
SK284263B6 (sk)	2004-12-01
JP4947824B2 (ja)	2012-06-06
NO325763B1 (no)	2008-07-14
ZA978431B (en)	1998-03-26
HUP9904121A3 (en)	2004-10-28
NO991385D0 (no)	1999-03-22
RU2193395C2 (ru)	2002-11-27
IL128565A0 (en)	2000-01-31
DK0939623T3 (da)	2002-06-10
CZ294641B6 (cs)	2005-02-16
DZ2314A1 (fr)	2002-12-28
CZ99599A3 (cs)	1999-06-16
IL128565A (en)	2003-02-12
WO1998013029A1 (en)	1998-04-02
CA2263921C (en)	2006-05-23
BR9711303A (pt)	1999-08-17
JP2001500885A (ja)	2001-01-23
HU226693B1 (en)	2009-06-29
PL332245A1 (en)	1999-08-30
AU4557097A (en)	1998-04-17
AU717711B2 (en)	2000-03-30

Legal Events

Date	Code	Title	Description
2002-06-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
ATE213627T1 (de)	2002-03-15	Orale zeitversetzt schnell freisetzende formulierung sowie verfahren zu deren herstellung
BR0206441A (pt)	2003-12-30	Composição de revestimento de pelìcula, revestimento de pelìcula cobrindo um núcleo farmacêutico, formulação farmacêutica de liberação modificada, e, processos para preparar uma composição de revestimento de pelìcula, um revestimento de pelìcula e uma formulação
ATE286871T1 (de)	2005-01-15	Mikrobielles verfahren zur herstellung von essigsäure sowie lösungsmittel zu deren extraktion aus der fermentationsbrühe
DE69822514D1 (de)	2004-04-22	Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung
DE3751463D1 (de)	1995-09-21	Ultravioletthärtbare Überzugsmasse und Verfahren zu deren Herstellung.
DE69811735D1 (de)	2003-04-03	Heterocyclische verbindungen zur hemmung der magensäureproduktion, verfahren zu ihrer herstellung und pharmazeutische zubereitungen davon
DE69937764D1 (de)	2008-01-24	Verfahren zur Herstellung eines Antireflektionsfilms
DE3880762D1 (de)	1993-06-09	Orale, acetaminophen enthaltende zusammensetzung mit gesteuerter arzneistoff-freisetzung und verfahren zu ihrer herstellung.
DE69608217D1 (de)	2000-06-15	Verfahren zur Herstellung der Akrylsäure
ATE246496T1 (de)	2003-08-15	Spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneiformen
ATE219499T1 (de)	2002-07-15	Lipopeptid-derivate, verfahren zu ihrer herstellung und ihre verwendung
ATE243193T1 (de)	2003-07-15	Benzocycloheptene, verfahren zu ihrer herstellung,pharmazeutische präparate die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln
ATE22077T1 (de)	1986-09-15	1-phenylisochinolinderivate und verfahren zu ihrer herstellung, diese verbindung enthaltende pharmazeutische praeparate und deren anwendung.
DE19681560T1 (de)	1998-08-20	Verfahren zur Herstellung von omega-Aminoalkansäure-Derivaten aus Cycloalkanonen
ATE851T1 (de)	1982-04-15	Hydroxyethyl-azole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
DE59510042D1 (de)	2002-03-21	2,2-dichloralkancarbonsäuren, verfahren zu ihrer herstellung diese enthaltende arzneimittel, und ihre verwendung zur behandlung der insulinresistenz
ATE818T1 (de)	1982-04-15	N-substituierte 2-cyanaziridine, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel, entsprechend substituierte aziridin-2-carbonsaeureamide und deren herstellung.
EP0268223A3 (de)	1990-03-28	Optisch aktive Gyrasehemmer, ihre Herstellung und Verwendung als Antibiotika
ATE85328T1 (de)	1993-02-15	Substituierte toluidine, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer.
ATE2840T1 (de)	1983-04-15	5-(2-hydroxy-3-thiopropoxy)-chromon-2carbons[uren, ihre salze und ester, verfahren zur herstellung und arzneimittel.
DE69516706D1 (de)	2000-06-08	Bis-2-aminopyridine, verfahren zu ihrer herstelung und ihre verwendung zur bekämpfung von parasitosen
ATE374177T1 (de)	2007-10-15	Cyclohexyl(alkyl)-propanolamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE3770287D1 (de)	1991-07-04	Neue n-glycosylamidderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
DE59607683D1 (de)	2001-10-18	Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
ATE174922T1 (de)	1999-01-15	Neue phosphanoxide, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel